Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients | recruiting | Phase 1 / Phase 2 | 91 | Curocell Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05870917 | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia | active not recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2026 |
| clinicaltrials |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 25 | Jennifer WoyachOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | recruiting | Phase 2 | 25 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07674810 | A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04587687 | Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma | recruiting | Phase 2 | 23 | University of California, DavisOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06107738 | Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma(IBEX) | recruiting | Phase 2 | 60 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07671378 | A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients | recruiting | Phase 2 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma(PrE0404) | completed | Phase 1 / Phase 2 | 43 | PrECOG, LLC.OTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04257578 | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06544785 | Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 106 | PETHEMA FoundationOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06785415 | Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 37 | Mayo ClinicOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217119 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217184 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 11 | Jun 25, 2026 | clinicaltrials |
| NCT07453095 | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy | recruiting | Phase 2 | 41 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03516617 | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 120 | Mayo ClinicOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT06522386 | GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07614360 | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM-16) | not yet recruiting | Phase 2 | 150 | GlaxoSmithKlineINDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT01415882 | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | completed | Phase 2 | 165 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03872180 | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 23 | Emory UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07247097 | ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma(ELDORADO) | not yet recruiting | Phase 2 | 160 | Massachusetts General HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02007044 | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05004064 | Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma(CARAMEL) | active not recruiting | Phase 2 | 48 | University College, LondonOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 33 | University of WashingtonOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07154264 | A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) | recruiting | Phase 2 | 66 | Dizal PharmaceuticalsINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07319897 | 68Ga-BCMA PET/CT in Multiple Myeloma | recruiting | Phase 2 / Phase 3 | 300 | Peking University First HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)(LINKER-MM8) | withdrawn | Phase 2 / Phase 3 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07507318 | Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission(DEL-MRD-CHID) | recruiting | Phase 2 | 69 | Rong TaoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01242930 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | completed | Phase 2 | 13 | Geron CorporationINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03556332 | A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation | active not recruiting | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07654465 | Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma(ROMA) | not yet recruiting | Phase 2 | 144 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07150091 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 20 | GlaxoSmithKlineINDUSTRY | 8 | Jun 16, 2026 | clinicaltrials |
| NCT07454382 | A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma | recruiting | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02427451 | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 87 | Kerry RogersOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | completed | Phase 2 | 20 | University of RochesterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04998786 | A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."(I2D IFM2021_03) | active not recruiting | Phase 2 | 75 | Nantes University HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma(BELAMI) | not yet recruiting | Phase 1 / Phase 2 | 44 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647432 | HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV(HEME-25) | not yet recruiting | Phase 2 / Phase 3 | 17 | University of Illinois at ChicagoOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | active not recruiting | Phase 1 / Phase 2 | 190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04113226 | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma(Relyage) | completed | Phase 2 | 1 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04324112 | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | active not recruiting | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2026source: clinicaltrials